tbuckley/cabot-search huggingface dataset:
EXTH-23. PRECLINICAL ANALYSIS OF COMBINATORIAL GLIOBLASTOMA THERAPY WITH THE PRODRUG-MEDIATED GENE THERAPY VECTOR AdV-tk AND IMMUNE CHECKPOINT INHIBITION
Authors: Maria Carmela Speranza, Kazue Kasai, Franz Ricklefs, Sarah R. Klein, Carmela Passaro, Nakashima Hiroshi, Johanna Kaufmann, Agnieszka Bronisz, Estuardo Aguilar-Cordova, Brian W. Guzik, Gordon J. Freeman, David A. Reardon, Patrick Wen, E. Antonio Chiocca, Sean E. Lawler
Journal: Neuro-Oncology (2016)

While the brain has traditionally been considered to be an immune-privileged site, evidence supporting the use of immunotherapeutics has been rapidly accumulating. Given that virus-based cancer therapies can be immunostimulatory and immune-checkpoint inhibitors block tumor-induced T-cell exhaustion, the combination of these two approaches offers a potentially synergistic interaction. One of the molecular underpinnings of T-cell exhaustion is the expression of Programmed Death-1 (PD1) on T-cells that recognizes its ligand PD-L1. AdV-TK is an immunostimulatory virus-based approach, known as Gene-Mediated Cytotoxic Immunotherapy (GMCI), that involves the intra-tumoral delivery of a non-replicating adenoviral vector carrying the Herpes virus thymidine kinase gene(TK) followed by administration of an anti-herpetic prodrug(ganciclovir-GCV) and recently showed encouraging results in a Phase II trial in glioblastoma(Wheeler et al.,2016). To provide a rationale for this therapeutic combination we investigated PD-L1 expression during GMCI therapy in human and mouse glioma cells in vitro and found that there was a consistent increase in cell surface PD-L1 levels. Interestingly, this was not associated with an increase of mRNA or protein. We also show that GMCI induces a type-I interferon response, and that the release of IFNβ is at least partially responsible for autocrine/paracrine PD-L1 up-regulation. In vivo studies using an intracranial GL261 model showed high levels of long term survivors in the GMCI/PD1 combination(11/14), compared with GMCI(6/16), anti-PD1(5/12) and controls(0/11). In addition, tumor infiltrating lymphocytes after GMCI showed an increase in CD8+, CD8+/GranzymeB+, and CD8+/IFNγ+/TNFα+cells suggestive of cytotoxic T-cell activation. However, there was also a significant increase in CD4+, CD4+/FoxP3+, and IL-10 indicating a significant infiltration by Tregs, releasing immunosuppressive cytokines. Additionally, there was a significant increase in PD1+/TIM3+ T-cells, indicative of an immunosuppressive microenvironment. Overall, our data show that GMCI/anti-PD1 combinatorial therapy is effective in a syngeneic tumor model, and strongly support clinical trials of GMCI/checkpoint inhibitor combinations in glioblastoma patients.
Treatment of Myelofibrosis Using I.V. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation Is Feasible and Results in Hematologic Responses – Long-Term Follow-up and Final Analysis of a One-Armed Clinical Study and of Individual Cases
Authors: Eike C. Buss, Julian Topaly, Hans H. Kreipe, Stefan Fruehauf, Anthony D. Ho
Journal: Blood (2011)
Solitary PSMA-Positive Pulmonary Metastasis in Biochemical Relapse of Prostate Cancer
Authors: Nils Groe Hokamp, Carsten Kobe, Eric Linzenich, David Maintz, Alexander Drzezga
Journal: Clinical Nuclear Medicine (2017)

A 63-year-old man with a history of prostate cancer, treated with resection, radiation, and androgen-depriving therapy over 4 years, was referred to our department with suspicion of recurrence based on increased blood PSA levels (1.60 ng/mL). Ga PSMA PET/CT identified a solitary, PSMA-positive pulmonary nodule in the right lung. After resection, histologic analysis confirmed prostatic origin, and the blood PSA level decreased to 0.13 ng/mL. Solitary pulmonary metastasis from prostate cancer is rare. The benefits of local treatment of a single metastasis even in advanced disease are disputed among oncologists. Here, biochemical response to resection was excellent.
May mutational status influence the metastatic pattern of colorectal cancer patients?
Authors: E. Ongaro, M. Bonotto, L. Gerratana, M. Casagrande, L. Ferrari, D. Iacono, S.K. Garattini, V. Fanotto, D. Basile, M. Cattaneo, K. Rihawi, M. Giovannoni, N. Pella, P. Ermacora, G.G. Cardellino, G. Aprile, G. Fasola
Journal: Annals of Oncology (2016)
Prognostic value of the neutrophil-to-lymphocyte ratio in advanced hepatocellular carcinoma: An exploratory analysis from the ARQ197-215 study
Authors: N. Personeni, L. Giordano, G. Abbadessa, C. Porta, I. Borbath, B. Daniele, S. Salvagni, J.-L. van Laethem, H. Van Vlierberghe, J. Trojan, A. Weiss, A. Gasbarrini, D. Shuster, E.N. De Toni, M. Lencioni, S. Miles, M.E. Lamar, B. Schwartz, A. Santoro, L. Rimassa
Journal: Annals of Oncology (2016)
Duodenal neoplasm in screening esophagogastroduodenoscopy
Authors: T. Nakamura, Y. Kon, S. Shibata, K. Konuma, T. Sanada, H. Gonda, Y. Suto, K. Kobayashi, N. Takita, M. Shimura, H. Yoshida, A. Suzuki, S. Onuki, M. Fukuda, C. Aoyagi, Y. Hasegawa, A. Nishiwaki
Journal: Annals of Oncology (2016)
Survival of patients with head and neck (H&amp;N) cancers: a nationwide study from France in 2008-2012 (EPICORL study)
Authors: F. Huguet, S. Témam, Y. Pointreau, S.P. Thiébaut, M. Bec, L. Lévy-Bachelot, C. Even, L. Geoffrois, M. Schwarzinger
Journal: Annals of Oncology (2016)
EXTH-35. THERAPEUTIC TARGETING OF TGF-β1/2 IN GLIOBLASTOMA USING NOVEL ANTISENSE OLIGONUCLEOTIDES
Authors: Alex Papachristodoulou, Michael Weller, Kathy Hasenbach, Michel Janicot, Patrick Roth
Journal: Neuro-Oncology (2016)

Transforming growth factor (TGF)-β is a potent cytokine with multiple biological activities, which has become an attractive target in glioblastoma because of its immunosuppressive properties and its role in angiogenesis, migration and invasion. Although the pathogenic function of TGF-β1 and TGF-β2 in glioblastoma is well defined, therapeutic targeting remains a challenge. Here we characterize the effects of two novel TGF-β1- or TGF-β2-specific phosphorothioate locked nucleic acid (LNA)-modified antisense oligonucleotide gapmers, ISTH1047 and ISTH0047 respectively, on the downstream signaling and growth of human LN-308 and murine SMA-560 glioma cells in vitro. Furthermore, we determined the effect of both antisense molecules on target inhibition and survival in orthotropic xenogeneic (LN-308) and syngeneic (SMA-560) in vivo glioma models. Both antisense oligonucleotides silence their corresponding target and inhibit downstream SMAD-2 phosphorylation in a concentration- and time-dependent manner. Moreover, inhibition of TGF-β1 or TGF-β2 mRNA expression by ISTH1047 or ISTH0047 reduces both the migrating and invasive potential of LN-308 and SMA-560 cells, with no effect on cell viability. Natural killer (NK) cells co-cultured with TGF-β2-depleted LN-308 glioma cells, exhibit increased lytic activity against the tumor cells. In vivo systemic administration of ISTH1047 or ISTH0047 significantly suppresses TGF-β1 or TGF-β2 mRNA expression, as well as the mRNA expression of the down-stream target PAI-1 in murine glioma-bearing hemispheres. Currently, we are investigating the therapeutic effect of ISTH1047 or ISTH0047 in the orthotopic glioma models. These data suggest that targeting TGF-β1 or TGF-β2 using these novel antisense oligonucleotides represents a promising approach to inhibit aberrant TGF-β signaling in glioblastoma with potential therapeutic benefit.
Concomitant chemoradiation (Ch-RT) in elderly newly diagnosed glioblastoma (GB) patients. Updated clinical outcome and molecular characteristics from the GLIOCAT study
Authors: M. Martinez-Garcia, E. Pineda, S. Del Barco, A. Estival, E. Verger, J. Marruecos, O. Gallego, M. Gil, R. Fuentes, J. Craven-Bartle Lamote de Grigno, A. Lucas, M. Macia, C. Mesía, J.M. Velarde, N. García, S. Villà, C. Balana
Journal: Annals of Oncology (2016)
Neutropenia grade ≥ 3 during treatment with docetaxel (DOC) is associated with an improved overall survival (OS): A retrospective analysis of the TAX327 phase III trial
Authors: A. Meisel, D. Vogt, R. de Wit, J.S. de Bono, O. Sartor, M. Eisenberger, F. Stenner-Liewen
Journal: Annals of Oncology (2016)
Phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies (NCT02572687); Phase 1a results
Authors: C.-C. Lin, T. Golan, J. Corral, V. Moreno, H.C. Chung, H. Wasserstrom, J. Yang, G. Mi, Y.-J. Bang
Journal: Annals of Oncology (2016)
Circulating microRNA-126 and epidermal growth factor-like domain 7 protein predict recurrence of colon cancer in patients treated with neoadjuvant chemotherapy
Authors: T.F. Hansen, A.L. Carlsen, J.T. Tanassi, N.H.H. Hegaard, F.O. Larsen, F.B. Soerensen, L.H. Jensen, A. Jakobsen
Journal: Annals of Oncology (2016)
Related Myeloablative Stem Cell Transplantation (SCT) to Cure Sickle Cell Anemia (SCA): Update of French Results
Authors: Francoise Bernaudin, Marie Robin, Christèle Ferry, Karima Yacouben, Jean-Hugues Dalle, Régis Peffault de Latour, Yves Bertrand, Corinne Pondarre, Mathieu Kuentz, Jean-Pierre Vannier, Alain Fischer, Isabelle Thuret, Patrick Lutz, Pierre Bordigoni, Pierre Rohrlich, Jean-Louis Stephan, Nathalie Dhedin, Jean Paul Vernant, Jean-Yves Cahn, Francois Demeocq, Bernard Rio, Dominique Bories, Eliane Gluckman, Gérard Socié
Journal: Blood (2010)
Quantitation of WT1 Transcripts by Copy Number Provides a Sensitive Indication of Minimal Residual Disease (MRD) and Response to Adoptive Cell Therapy in Patients Transplanted for Ph(+) CML.
Authors: Annamalai Selvakumar, Aisha Hasan, Vidhi Desai, Gianfranco Pittari, Lorna Barnett, Esperanza B Papadopoulos, Richard J O'Reilly
Journal: Blood (2009)
Risk Factors for Late Infections after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Related Donor.
Authors: Marie Robin, Raphaël Porcher, Renato De Castro Araujo, Régis Peffault de Latour, Agnès Devergie, Vanderson Rocha, Jérome Larghero, Hélène Espérou, Lionel Adès, Eliane Gluckman, Patricia Ribaud, Jean-Yves Mary, Gérard Socié
Journal: Blood (2006)
Microvascular density and mast cell density positive to tryptase correlate with c-Kit receptor expression in early breast cancer patients
Authors: I. Marech, M. Ammendola, C. Leporini, R. Patruno, M. Luposella, R. Sacco, G. Sammarco, V. Zuccalà, N. Zizzo, E. Russo, G. De Sarro, C.D. Gadaleta, G. Ranieri
Journal: Annals of Oncology (2016)
Significance of upper and lower gastrointestinal endoscopy during small intestinal screening in non-Hodgkin's lymphoma
Authors: Ken Sato, Hiroyuki Kuroda, Shogo Miura, Hiroto Horiguchi, Takanori Shibata, Naoki Uemura, Tomoyuki Abe, Shigeyuki Fujii, Masahiro Maeda, Junji Kato
Journal: Annals of Oncology (2016)
SDF-1α Induced NF-κB Activation Promotes Adhesion and Trans-Endothelial Migration of Prostate Cancer Cells by Enhancing the Expression of the Chemokine Receptor CXCR4.
Authors: Promil Kukreja, Asim B. Abdel-Mageed, Debasis Mondal, Krishna C. Agrawal
Journal: Blood (2004)
Long-term explerience in the management of adolescents and young adults with cancer referred to a regional tertiary center for multidisciplinary care
Authors: M. Melián Sosa, R. Díaz, E. Navarro, J.A. Mendez, M.E. Medina, A. Torres, E. García, D. Akhoundova, J. Aparicio
Journal: Annals of Oncology (2016)
Combination Of Arsenic and Interferon-a Inhibits Expression Of KSHV Latent Transcripts and Synergistically Improves Survival Of Mice With Primary Effusion Lymphomas
Authors: Hiba El Hajj, Jihane Ali, Akram Ghantous, Dana Hodroj, Ahmad Daher, Ahmad Daher, Kazem Zibara, Chloé Journo, Zaher K. Otrock, Ghazi Zaatari, Renaud Mahieux, Marwan El Sabban, Raghida Abou Merhi, Ali Bazarbachi
Journal: Blood (2013)
Minimal Residual Disease in Adults with Advanced Relapsed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Treated with Marqibo® (vinCRIStine sulfate LIPOSOME injection)
Authors: Olivia R. Deitcher, Stuart L. Goldberg, Wendy Stock, Gary J. Schiller, John Lister, Jeffrey A. Silverman, Steven R. Deitcher, Susan O'Brien
Journal: Blood (2012)
Agnostos precision medicine project in patients (PTS) with cancer of unknown primary (CUP)
Authors: E. Geuna, S. Benvenuti, F. Verginelli, D. Galizia, S. Siena, G.M. Stella, A. Gentile, M. Milan, A.R. Virzi', A. D'ambrosio, P. Cassoni, R. Senetta, A. Balsamo, M. Spione, A. Nuzzo, A. Sapino, S. Marsoni, C. Boccaccio, P.M. Comoglio, F. Montemurro
Journal: Annals of Oncology (2016)
Deubiquitylating Enzyme Rpn11/POH1/PSMD14 As Therapeutic Target in Multiple Myeloma
Authors: Yan Song, Arghya Ray, Deepika Sharma Das, Mehmet K. Samur, Ruben D. Carrasco, Nikhil C. Munshi, Dharminder Chauhan, Kenneth C. Anderson
Journal: Blood (2016)
BMET-10. STEREOTACTIC RADIOSURGERY FOR PATIENTS WITH TEN OR MORE BRAIN METASTASES
Authors: Elliot Schiff, Luke Swaszek, Jonathan Knisely, Aditya Halthore, Sussan Salas, Nina Kohn, Michael Schulder
Journal: Neuro-Oncology (2016)

To evaluate the efficacy of Gamma Knife radiosurgery (GKRS) as treatment in patients with 10 or more metastatic brain tumors. Between February 2014 and January 2016, 20 patients were treated with GKRS for 10 or more brain metastases. We retrospectively analyzed the data from these patients, with survival and tumor control as primary endpoints. Brain volumes treated with 8 Gy and 12 Gy were measured to explore volume of treated tissue as a contributing factor to tumor control. Pre-treatment and post-treatment magnetic resonance imaging (MRI) studies were reviewed at intervals of 3 months, as were patient records on site. Of the 20 patients treated, 3 were excluded due to insufficient follow-up data. For the 17 included patients the median age was 61 (range 19-76). These patients were treated for a total of 323 tumors, with a median of 17 tumors per patient (10-34). The median survival for these patients was 12.5 months (1.3-16.9). Patient survival was censored at the time of data collection, and the true upper limit of survival is higher than recorded here. The mean percent of brain volume treated was 0.9, with a median of 0.41 (0.07 – 3.38). The mean percent of brain volume that received a dose of 12 Gy was 5.0 (0 – 21.0), and of 8 Gy was 9.0 (1.0 – 31.0). For each of the first three 3-month intervals, the median percent of tumor control was 97%, 96%, and 100%, respectively in the patients with available data. GKRS effectively treats and controls brain tumors, even in patients presenting with 10 or more tumors simultaneously. The number of tumors initially present was not found to have a significant correlation with general tumor control.
Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma
Authors: Nicolas A. Giraldo, Etienne Becht, Yann Vano, Florent Petitprez, Laetitia Lacroix, Pierre Validire, Rafael Sanchez-Salas, Alexandre Ingels, Stephane Oudard, Audrey Moatti, Benedicte Buttard, Sarah Bourass, Claire Germain, Xavier Cathelineau, Wolf H. Fridman, Catherine Sautès-Fridman
Journal: Clinical Cancer Research (2017)

Purpose: The efficacy of PD-1 checkpoint blockade as adjuvant therapy in localized clear cell renal cell carcinoma (ccRCC) is currently unknown. The identification of tumor microenvironment (TME) prognostic biomarkers in this setting may help define which patients could benefit from checkpoint blockade and uncover new therapeutic targets.Experimental Design: We performed multiparametric flow cytometric immunophenotypic analysis of T cells isolated from tumor tissue [tumor-infiltrating lymphocytes (TIL)], adjacent non-malignant renal tissue [renal-infiltrating lymphocytes (RIL)], and peripheral blood lymphocytes (PBL), in a cohort of patients (n = 40) with localized ccRCC. Immunophenotypic data were integrated with prognostic and histopathologic variables, T-cell receptor (TCR) repertoire analysis of sorted CD8+PD-1+ TILs, tumor mRNA expression, and digital quantitative immunohistochemistry.Results: On the basis of TIL phenotypic characterization, we identified three dominant immune profiles in localized ccRCC: (i) immune-regulated, characterized by polyclonal/poorly cytotoxic CD8+PD-1+Tim-3+Lag-3+ TILs and CD4+ICOS+ cells with a Treg phenotype (CD25+CD127-Foxp3+/Helios+GITR+), that developed in inflamed tumors with prominent infiltrations by dysfunctional dendritic cells and high PD-L1 expression; (ii) immune-activated, enriched in oligoclonal/cytotoxic CD8+PD-1+Tim-3+ TILs, that represented 22% of the tumors; and (iii) immune-silent, enriched in TILs exhibiting RIL-like phenotype, that represented 56% of patients in the cohort. Only immune-regulated tumors displayed aggressive histologic features, high risk of disease progression in the year following nephrectomy, and a CD8+PD-1+Tim-3+ and CD4+ICOS+ PBL phenotypic signature.Conclusions: In localized ccRCC, the infiltration with CD8+PD-1+Tim-3+Lag-3+ exhausted TILs and ICOS+ Treg identifies the patients with deleterious prognosis who could benefit from adjuvant therapy with TME-modulating agents and checkpoint blockade. This work also provides PBL phenotypic markers that could allow their identification. Clin Cancer Res; 23(15); 4416-28. ©2017 AACR.
Induction of apoptosis in MMTV/PyMT mammary gland tumors with oral zebularine
Authors: Min Chen, Donna Voeller, Melinda Hollingshead, Sherry X Yang, Kent Hunter, Giuseppe Giaccone, Victor Marquez, Patricia Steeg, Maria Zajac-Kaye
Journal: Cancer Research (2008)

2611  Zebularine, a synthetic analog of cytidine and a potent inhibitor of cytidine deaminase, has recently been identified as a DNA methylation inhibitor. In addition, nude mice with EJ6 bladder cancer xenografts showed induction of p16 expression and reduction of tumor growth following oral zebularine as compared to untreated controls (Cheng et al JNCI 95 p399 2003). We studied the effect of zebularine on mammary tumor growth in MMTV-PyMT transgenic mice which develop mammary tumors within 60 days with 100 percent penetrance. The mice were randomized at 46 days of age into control (n=25) and zebularine treated (n=25) groups, which were given 5 mg/ml of zebularine in drinking water. Tumors were measured twice weekly and the median tumor weight was calculated for each group. We found a significant delay in the occurrence of tumors in both the axillary and inguinal mammary glands in zebularine treated mice as compared to untreated controls. We observed a statistically significant (p = 0.01) reduction in total tumor burden at 94 days of age when the mice were sacrificed. To determine the mechanism of the zebularine tumor effect we examined the histology of the treated and control tumors. After 48 days of drug treatment the tumors were predominantly necrotic compared to the untreated animals and a high apoptotic index was observed as early as 13 days by tunel assay. A negligible level of apoptotic cells was found in tumors from control animals. Although we did not observe induction of p16 levels after 13, 23 and 48 days of zebularine treatment, we did observe induction of p21 expression, suggesting a tissue specific effect on patterns of gene demethylation. Immunoblot analysis showed depletion of DNMT1 and partial depletion of DNMT3b after zebularine treatment. To investigate the effect of zebularine on global gene expression profiles, microarray analyses were performed on tumors that were excised at 13, 23 and 48 days from both treated and untreated mice. This analysis confirmed p21 induction and the absence of p16 induction. In addition, we identified upregulation of four additional methylation regulated genes (1.5 to 2.4 fold increase) as well as a set of candidate cancer genes that may play a role in cell growth and apoptosis. Our results suggest that the pattern of DNA demethylation following zebularine treatment is restricted to specific sets of genes and that cell death and necrosis contribute to the delay in tumor growth observed in mice continuously exposed to the oral intake of the drug.
Cercival lymph node metastasis of squamous cell carcinoma of an unknown primary (SCCUP): a single institutional review
Authors: J.P. Silva, M.T. Alexandre, D. Ferreira, M. Ramos, P. Pereira, N. Ferreira, I. Sargento, E. Netto, M. Magalhaes, M. Ferreira, A. Moreira
Journal: Annals of Oncology (2016)
RARE-28. CLINICAL FEATURES OF CEREBELLAR GLIOBLASTOMA
Authors: Sho Tamai, Katsuyoshi Miyashita
Journal: Neuro-Oncology (2016)

Cerebellar glioblastoma (GBM) is a rare tumor in adults that accounts for 2% of all cases of GBMs. Due to their rarity, cerebellar GBMs are not completely understood about the pathogenesis and the prognosis. Here, we compared cerebellar GBM cases and cerebral GBM cases on their clinical features and weighed these differences. We assessed the clinical records of patients with GBMs between 2011 and 2016 at the Department of Neurosurgery Kanazawa University Hospital. 6 patients with cerebellar GBMs (3 males, 3 females; range 35-78 years old; median age, 66 years old) and 42 patients with cerebral GBMs (24 males, 18 females; range 41-83 years old; median age, 68 years old). All cases received concomitant chemoradiotherapies with temozolomide. We evaluated six factors; the period of onset to visit hospital, operative removal rate, Karnofsky Performance Status (KPS) score, progression free survival (PFS), overall survival (OS) and immunohistochemical analyses (MIB-1 staining index, MGMT promoter methylation and IDH-1 mutation). The period of onset to visit hospital was significantly shorter in cerebellar GBM cases (average; 2 weeks) compared with cerebral GBM cases (average; 5 weeks; p=0.036). OS was significantly shorter in cerebellar GBM cases (range; 6.9-19.2 median; 13.1 months) than cerebral GBM cases (range; 8.1-15.5, median; 16.4 months; p=0.027). MIB-1 staining indices were higher in cerebellar GBM cases (range; 30-85, average; 55%) compared with cerebral GBM cases (range; 3-75, average; 27.8%; p=0.049). Our data suggested that the cerebellar GBMs are rapid onset of symptoms and the poor prognosis because of their higher proliferative capacities.
Rociletinib-associated cataracts in EGFR-mutant NSCLC
Authors: Z. Piotrowska, E. Liu, A. Varga, M. Thakur, V. Narayanan, S.V. Liu, J. Neal, M. Spiegel, B. Solomon, H. Yu, S.-H.I. Ou, V.A. Papadimitrakopoulou, S. Gadgeel, D.R. Camidge, J.-C. Soria, H. Wakelee, J. Goldman, K. Kopani, L. Rolfe, L.V. Sequist
Journal: Annals of Oncology (2016)
68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Chordoma
Authors: Thorsten Derlin, Jan M. Sohns, Katja Hueper
Journal: Clinical Nuclear Medicine (2017)

Chordoma is a rare slow-growing neoplasm of neuroectodermal origin, which frequently recurs after removal and has the potential to metastasize. We present the case of a 53-year-old man with metastasizing chordoma who underwent F-FDG and Ga-DOTA-TATE PET/CT for restaging of disease and for evaluation of targeted radionuclide therapy potential. On both F-FDG and Ga-DOTA-TATE PET scans, increased tracer accumulation was observed in chordoma metastases. Besides the increased glucose metabolism in chordoma, this case highlights the potential of Ga-DOTA-TATE PET/CT for restaging of chordoma as well the option of targeted radionuclide therapy in this entity.
Establishing Safety in the Clinic for the First Lentiviral Vector To Be Tested in Humans.
Authors: Boro Dropulic, Laurent Humeau, Vladimir Slepushkin, Xiaobin Lu, Peter Manilla, Tessio Rebello, Cathleen Afable, Kim Lacy, Cathy Ybarra, Bruce Levine, Carl June, Rob Roy MacGregor
Journal: Blood (2004)
Reduced-Dosage of Three Drugs Combination of Cyclophosphamide, Bortezomib and Dexamethasone (reduced-CyBorD) Retains High Response Rate with Less Toxicities in Elderly Patients with Multiple Myeloma
Authors: Hideo Yagi, Ryosuke Fujiwara, Keigo Sano, Fujita Mariko, Takashi Iizuka, Keiko Yamazaki, Hitoshi Hanamoto, Kazuo Tubaki
Journal: Blood (2012)
Awareness and consideration of malnutrition among italian oncologists: insights from an exploratory survey
Authors: R. Caccialanza, P. Pedrazzoli, E. Cereda, G. Farina, P. Cotogni, C. Pinto, C. Gavazzi, C. Gandini, M.T. Nardi, V. Zagonel
Journal: Annals of Oncology (2016)